An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348 With Co-administration of CKD-828, D097 and D337 in Healthy Adult Volunteers
Latest Information Update: 05 Feb 2021
Price :
$35 *
At a glance
- Drugs CKD-348 (Primary) ; D 097; D 337; Levamlodipine/telmisartan
- Indications Dyslipidaemias; Hypertension
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 02 Feb 2021 Status changed from not yet recruiting to completed.
- 16 Oct 2020 New trial record